Difference between revisions of "Gallbladder cancer - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "|Years of enrollment" to "|Dates of enrollment") |
m |
||
| Line 4: | Line 4: | ||
=Neoadjuvant therapy= | =Neoadjuvant therapy= | ||
==No neoadjuvant therapy== | ==No neoadjuvant therapy== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen=== | ===Regimen=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 21: | Line 21: | ||
|} | |} | ||
''No systemic therapy prior to surgery.'' | ''No systemic therapy prior to surgery.'' | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*[[Surgery#Surgical_resection|Surgical resection]] | *[[Surgery#Surgical_resection|Surgical resection]] | ||
| + | </div></div> | ||
===References=== | ===References=== | ||
#'''ECOG-ACRIN EA2197:''' NCT04559139 | #'''ECOG-ACRIN EA2197:''' NCT04559139 | ||
| + | |||
| + | =Adjuvant therapy= | ||
| + | ==Observation== | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
| + | ===Regimen=== | ||
| + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 20%"|Study | ||
| + | !style="width: 20%"|Dates of enrollment | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 20%"|Comparator | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://doi.org/10.1016/s0140-6736(22)02038-4 Nakachi et al 2023 (ASCOT)] | ||
| + | |2013-09-09 to 2018-06-22 | ||
| + | | style="background-color:#1a9851" |Phase 3 (C) | ||
| + | |[[Gallbladder_cancer#S-1_monotherapy|S-1]] | ||
| + | | style="background-color:#d73027" |Inferior OS | ||
| + | |- | ||
| + | |} | ||
| + | ''No systemic therapy after surgery.'' | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
| + | ====Preceding treatment==== | ||
| + | *[[Surgery#Surgical_resection|Surgical resection]] | ||
| + | </div></div> | ||
| + | ===References=== | ||
| + | #'''ASCOT:''' Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023 Jan 21;401(10372):195-203. PMID: 36681415. [https://doi.org/10.1016/s0140-6736(22)02038-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36681415/ Pubmed] UMIN000011688 | ||
=Metastatic or unresectable disease, all lines of therapy= | =Metastatic or unresectable disease, all lines of therapy= | ||
==Best supportive care== | ==Best supportive care== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen=== | ===Regimen=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 48: | Line 76: | ||
|} | |} | ||
''No active antineoplastic treatment.'' | ''No active antineoplastic treatment.'' | ||
| − | + | </div> | |
===References=== | ===References=== | ||
Revision as of 14:44, 11 April 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main gallbladder cancer page for current regimens.
Neoadjuvant therapy
No neoadjuvant therapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Awaiting publication (ECOG-ACRIN EA2197) | 2020-ongoing | Phase 3 (C) | GC | In progress |
No systemic therapy prior to surgery.
Subsequent treatment
References
- ECOG-ACRIN EA2197: NCT04559139
Adjuvant therapy
Observation
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Nakachi et al 2023 (ASCOT) | 2013-09-09 to 2018-06-22 | Phase 3 (C) | S-1 | Inferior OS |
No systemic therapy after surgery.
Preceding treatment
References
- ASCOT: Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023 Jan 21;401(10372):195-203. PMID: 36681415. link to original article Pubmed UMIN000011688
Metastatic or unresectable disease, all lines of therapy
Best supportive care
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Sharma et al. 2010 | 2006-2008 | Randomized (C) | 1. FUFA | Did not meet primary endpoint of OS |
| 2. mGEMOX | Seems to have inferior OS |
No active antineoplastic treatment.
References
- Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010 Oct 20;28(30):4581-6. Epub 2010 Sep 20. link to original article contains dosing details in abstract PubMed